| Primary |
| Stent Placement |
36.3% |
| Percutaneous Coronary Intervention |
14.8% |
| Acute Coronary Syndrome |
11.4% |
| Acute Myocardial Infarction |
10.3% |
| Myocardial Infarction |
4.4% |
| Coronary Arterial Stent Insertion |
3.1% |
| Coronary Artery Disease |
2.8% |
| Antiplatelet Therapy |
2.6% |
| Angioplasty |
2.1% |
| Hypertension |
2.0% |
| Angina Pectoris |
1.6% |
| Thrombosis In Device |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Diabetes Mellitus |
1.2% |
| Anticoagulant Therapy |
1.1% |
| Prophylaxis |
0.8% |
| Angina Unstable |
0.7% |
| Product Used For Unknown Indication |
0.7% |
| Cardiac Disorder |
0.6% |
| Hypercholesterolaemia |
0.6% |
|
| Thrombosis In Device |
24.9% |
| Myocardial Infarction |
7.2% |
| Death |
6.9% |
| In-stent Coronary Artery Restenosis |
5.4% |
| Cerebrovascular Accident |
5.2% |
| Haemorrhage |
5.0% |
| Acute Myocardial Infarction |
4.7% |
| Chest Pain |
4.5% |
| Drug Dose Omission |
3.9% |
| Thrombosis |
3.6% |
| Transient Ischaemic Attack |
3.4% |
| Off Label Use |
3.2% |
| Coronary Artery Restenosis |
3.1% |
| Stent Placement |
3.1% |
| Gastrointestinal Haemorrhage |
2.9% |
| Haemorrhage Intracranial |
2.9% |
| Angina Pectoris |
2.7% |
| Device Occlusion |
2.7% |
| Hospitalisation |
2.5% |
| Drug Ineffective |
2.1% |
|
| Secondary |
| Stent Placement |
20.3% |
| Percutaneous Coronary Intervention |
16.4% |
| Acute Myocardial Infarction |
13.0% |
| Acute Coronary Syndrome |
11.7% |
| Product Used For Unknown Indication |
10.5% |
| Myocardial Infarction |
4.7% |
| Antiplatelet Therapy |
2.7% |
| Anticoagulant Therapy |
2.5% |
| Thrombosis Prophylaxis |
2.3% |
| Vascular Operation |
2.1% |
| Coronary Artery Disease |
2.0% |
| Hypertension |
1.9% |
| Coronary Arterial Stent Insertion |
1.8% |
| Coronary Revascularisation |
1.6% |
| Angina Pectoris |
1.5% |
| Angioplasty |
1.2% |
| Blood Cholesterol Increased |
0.9% |
| Cardiac Disorder |
0.9% |
| Colitis Ulcerative |
0.9% |
| Diabetes Mellitus |
0.9% |
|
| Thrombosis In Device |
30.5% |
| Death |
7.3% |
| Drug Ineffective |
5.8% |
| In-stent Coronary Artery Restenosis |
5.8% |
| Acute Myocardial Infarction |
5.1% |
| Coronary Artery Restenosis |
4.0% |
| Overdose |
4.0% |
| Angina Pectoris |
3.3% |
| Gastrointestinal Haemorrhage |
3.3% |
| Haemorrhage Intracranial |
3.3% |
| Intracardiac Thrombus |
3.3% |
| Myocardial Infarction |
3.3% |
| Platelet Function Test Abnormal |
3.3% |
| Haemorrhage |
2.9% |
| Cerebrovascular Accident |
2.5% |
| Chest Pain |
2.5% |
| Off Label Use |
2.5% |
| Thrombosis |
2.5% |
| Transient Ischaemic Attack |
2.5% |
| Anaemia |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
58.6% |
| Hypertension |
7.7% |
| Blood Cholesterol Increased |
4.1% |
| Cardiac Disorder |
4.1% |
| Anticoagulant Therapy |
2.6% |
| Diabetes Mellitus |
2.2% |
| High Density Lipoprotein Decreased |
2.0% |
| Gastrooesophageal Reflux Disease |
2.0% |
| Stent Placement |
1.9% |
| Chronic Obstructive Pulmonary Disease |
1.7% |
| Rheumatoid Arthritis |
1.5% |
| Prophylaxis |
1.4% |
| Drug Use For Unknown Indication |
1.4% |
| Coronary Artery Disease |
1.3% |
| Atrial Fibrillation |
1.3% |
| Depression |
1.2% |
| Hyperlipidaemia |
1.2% |
| Cardiovascular Event Prophylaxis |
1.2% |
| Blood Pressure Abnormal |
1.2% |
| Myocardial Infarction |
1.1% |
|
| Flushing |
19.4% |
| Myocardial Infarction |
12.4% |
| Pruritus |
9.1% |
| Nausea |
5.8% |
| Paraesthesia |
5.0% |
| Vomiting |
4.1% |
| Dyspnoea |
3.7% |
| Fatigue |
3.7% |
| Myalgia |
3.7% |
| Weight Decreased |
3.7% |
| Coronary Artery Occlusion |
3.3% |
| Drug Ineffective |
3.3% |
| Erythema |
3.3% |
| Blood Glucose Increased |
2.9% |
| Haemorrhage |
2.9% |
| Skin Burning Sensation |
2.9% |
| Stent Placement |
2.9% |
| Wrong Technique In Drug Usage Process |
2.9% |
| Feeling Hot |
2.5% |
| Malaise |
2.5% |
|
| Interacting |
| Acute Myocardial Infarction |
35.7% |
| Coronary Artery Disease |
28.6% |
| Cardiac Failure |
7.1% |
| Diabetes Mellitus |
7.1% |
| Stent Placement |
7.1% |
| Arrhythmia |
3.6% |
| Hypotension |
3.6% |
| Product Used For Unknown Indication |
3.6% |
| Sedation |
3.6% |
|
| Blood Glucose Fluctuation |
14.3% |
| Drug Interaction |
14.3% |
| Haemoglobin Decreased |
14.3% |
| Hypotension |
14.3% |
| Subarachnoid Haemorrhage |
14.3% |
| Toxic Epidermal Necrolysis |
14.3% |
| Upper Gastrointestinal Haemorrhage |
14.3% |
|
